Skip to content
XOMA
  • About Us
    • Overview
    • Management Team
    • Board of Directors
    • Contact Us
  • Royalty Portfolio
  • Opportunities
    • Overview
    • Royalty Acquisition
    • Assets Available for Licensing
      • Phage Display Platform
      • Ebopiprant
      • Anti-prolactin Antibody
      • XMetA Portfolio
  • News
    • Company & Partner News
    • Press Releases
  • Investors
    • Overview
    • News & Events
    • Financial Information
    • Stock Data
    • Analyst Coverage
    • SEC Filings
    • Governance
  • Contact
XOMA
XOMA
  • About Us
    • Overview
    • Management Team
    • Board of Directors
    • Contact Us
  • Royalty Portfolio
  • Opportunities
    • Overview
    • Royalty Acquisition
    • Assets Available for Licensing
      • Phage Display Platform
      • Ebopiprant
      • Anti-prolactin Antibody
      • XMetA Portfolio
  • News
    • Company & Partner News
    • Press Releases
  • Investors
    • Overview
    • News & Events
    • Financial Information
    • Stock Data
    • Analyst Coverage
    • SEC Filings
    • Governance
  • Contact

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Company & Partner News
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Financial Information
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Overview
    • Charts
    • Historical Data
    • IRS Form 8937
  • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Management Team
    • Board of Directors
    • Board Committees
    • Governance Documents

Press Releases

XOMA to Present at Cowen Health Care Conference

Feb 28, 2012 4:05pm EST

XOMA to Present at 14th Annual BIO CEO & Investor Conference

Feb 06, 2012 4:05pm EST

XOMA Acquires U.S. Rights to Perindopril Franchise and Establishes Commercial Operations

Jan 17, 2012 4:05pm EST

XOMA Streamlines Operations to Invest in Value-Creating Activities

Jan 05, 2012 12:45pm EST

Photo Release -- XOMA Appoints John Varian as Chief Executive Officer

Jan 05, 2012 12:30pm EST

XOMA Secures $10 Million Term Loan

Jan 03, 2012 8:00am EST

XOMA Will Move Its Corporate Domicile to Delaware

Dec 30, 2011 4:05pm EST

XOMA Initiates Gevokizumab Phase 2 Study for Moderate to Severe Acne Vulgaris

Dec 21, 2011 8:00am EST

XOMA Announces Presentation and Webcast at BIO Investor Forum

Oct 18, 2011 4:05pm EDT

XOMA Announces Proposed Domestication to Delaware

Oct 04, 2011 4:50pm EDT
RSS
  • Prev
    • 1...
    • 24
    • 25
    • 26
    • 27
    • 28
    • 29
    • 30
    • 31
    • 32
    • 33
    • ...47
    Next
    • Email Alerts
    • RSS News Feed
    • Terms of Use

    © 2025 XOMA Royalty Corporation.  All rights reserved.

    All references to “portfolio” on this website refer strictly to milestone and/or royalty rights associated with a basket of drug products in development. All references to “assets” on this website refer strictly to milestone and/or royalty rights associated with individual drug product candidates in development. References to royalties or royalty rates strictly refer to future potential payment streams regardless of whether or not they are technically defined as royalties in the underlying contractual agreement; further, any rates referenced herein are subject to potential future contractual adjustments.

    • Follow us:
    © 2025 XOMA • Powered by GeneratePress
    Scroll back to top